Israel-developed app found effective in lowering blood pressure, study finds
Hello Heart’s connected blood pressure cuff and smartphone app allow users to self-manage their heart health and spot serious problems before they happen. Hello Heart, founded in 2013, integrates medication adherence reminders and personalized, clinically-based digital lifestyle change coaching. This research is the largest multi-year study on the effectiveness of digital therapy in the control of hypertension.
Researchers followed 28,189 adults with employer-sponsored health insurance who used the technology and the Hello Heart program. They found that the more people engaged in Hello Heart digital therapy, the more their blood pressure improved, especially in people with stage II, the most severe form of hypertension.
“This is the first published and peer-reviewed study to report long-term experience of a digital health application for blood pressure management, with clinically significant magnitude of association,” said Alexis Beatty, MD, MAS, cardiologist and associate. professor at the University of California at San Francisco and lead author of the study. “On average, participants used Hello Heart for 25 weeks, a level of commitment that I have not seen in other digital hypertension management programs. Sustained commitment and decreases in systolic blood pressure more than 20 mmHg can reduce the risk of heart attack, stroke, kidney disease and death.
The researchers found that for the majority of users, any level of engagement with the Hello Heart program was associated with a reduction in blood pressure. Additionally, Hello Heart has demonstrated its ability to capture hypertensive crises in both men and women and timely identify potential events before they become catastrophic. The results were statistically significant even after adjusting for demographic, socioeconomic, and behavioral factors.
“There is a lot of skepticism and cynicism around hypertension management solutions because for years there has been no effective solution, and current solutions generate low participant engagement. We are delighted that the study has demonstrated such strong and lasting clinical results over three years for Hello Heart users, ”said Maayan Cohen, CEO of Hello Heart. “It can be very uncomfortable and even scary for companies to submit their findings to peer review. We have been helping users with their heart health for several years and are proud to subject our clinical results to a peer review process that validates what we already know: Hello Heart has strong, sustained clinical impact, at scale. “